Results 31 to 40 of about 2,926,291 (344)

Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis

OncoImmunology, 2022
Nearly 40% of the advanced cancer patients will present brain metastases during the course of their disease, with a 2-year life expectancy of less than 10%.
Alberto Carretero-González, Marta Hergueta-Redondo, Sara Sánchez-Redondo, Pilar Ximénez-Embún, Luis Manso Sánchez, Eva Ciruelos Gil, Daniel Castellano, Guillermo de Velasco, Héctor Peinado   +8 more
doaj   +1 more source

Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial).

Radiotherapy and Oncology, 2021
BACKGROUND AND PURPOSE Brain metastasis impacts greatly on patients' quality of life and survival. The phase I NANO-RAD trial assessed the safety and maximum tolerated dose of systemic administration of a novel gadolinium-based nanoparticle, AGuIX, in ...
C. Verry, S. Dufort, J. Villa, M. Gavard, C. Iriart, S. Grand, J. Charles, B. Chovelon, J. Cracowski, J. Quesada, Christophe Mendoza, L. Sancey, Audrey Lehmann, F. Jover, J. Giraud, F. Lux, Y. Crémillieux, S. McMahon, P. Pauwels, D. Cagney, R. Berbeco, A. Aizer, E. Deutsch, M. Loeffler, G. Le Duc, O. Tillement, J. Balosso   +26 more
semanticscholar   +1 more source

Late-onset meningeal metastases in liposarcoma: A case report and review of the literature [PDF]

, 2006
Intracranial metastases from liposarcoma are rare and almost always preceded by the development of systemic tumour spread. We report here a case of liposarcoma with spread to the cranial nervous system 23 years after treatment of the primary tumour.
White, J., Cowie, F., Ferguson, M., Stewart, W.   +3 more
core   +1 more source

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

The Lancet, 2016
Summary Background Whole brain radiotherapy (WBRT) and dexamethasone are widely used to treat brain metastases from non-small cell lung cancer (NSCLC), although there have been no randomised clinical trials showing that WBRT improves either quality of ...
P. Mulvenna, M. Nankivell, R. Barton, C. Faivre-Finn, Paula Wilson, Elaine McColl, B. Moore, I. Brisbane, D. Ardron, T. Holt, Sally Morgan, Caroline Lee, K. Waite, N. Bayman, Cheryl A Pugh, Benjamin Sydes, Richard Stephens, Mahesh K. B. Parmar, R. Langley   +18 more
semanticscholar   +1 more source

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase 2 trial

The Lancet Oncology, 2020
Summary Background: We performed a phase II trial of pembrolizumab in patients with NSCLC or melanoma with untreated brain metastases to determine the activity of PD-1 blockade in the CNS.
S. Goldberg, K. Schalper, S. Gettinger, A. Mahajan, R. Herbst, A. Chiang, R. Lilenbaum, F. Wilson, S. Omay, James B. Yu, Lucia B. Jilaveanu, Thuy T. Tran, K. Pavlik, E. Rowen, H. Gerrish, A. Komlo, Richa Gupta, Hailey Wyatt, M. Ribeiro, Y. Kluger, Geyu Zhou, Wei Wei, V. Chiang, H. Kluger   +23 more
semanticscholar   +1 more source

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.

Journal of Thoracic Oncology, 2021
INTRODUCTION This exploratory analysis retrospectively evaluated outcomes in patients with advanced NSCLC to determine whether baseline brain metastases influenced the efficacy of first-line pembrolizumab plus chemotherapy versus chemotherapy alone ...
S. Powell, D. Rodríguez-Abreu, C. Langer, A. Tafreshi, L. Paz-Ares, H. Kopp, J. Rodríguez-Cid, D. Kowalski, Ying Cheng, T. Kurata, M. Awad, Jin-Ing Lin, Bin Zhao, M. Pietanza, B. Piperdi, M. Garassino   +15 more
semanticscholar   +1 more source

Outcome of Patients with Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases: Egyptian Experience [PDF]

Research in Oncology, 2016
Background: Lung cancer remains the most common primary tumor responsible for brain metastases making up to 40% to 50% of cases. Brain metastases from NSCLC is associated with poor prognosis. Aim: The aim of this study is to analyze the risk factors and
Salah Elmesidy, Hussam Zawam, Asmaa Hassan, Mohamed Abol-Kasem, Radwa Fawzy, Mahmoud Abdelsalam   +5 more
doaj   +1 more source

Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies

Cancers, 2021
Simple Summary Development of brain metastases is an important event for patients with breast cancer, and it affects both their survival and their quality of life.
A. García-Álvarez, A. Papakonstantinou, Mafalda Oliveira   +2 more
semanticscholar   +1 more source

Brain metastases: the role of clinical imaging

British Journal of Radiology, 2021
Imaging of brain metastases (BMs) has advanced greatly over the past decade. In this review, we discuss the main challenges that BMs pose in clinical practice and describe the role of imaging.
S. Derks, Astrid A M van der Veldt, M. Smits   +2 more
semanticscholar   +1 more source

Optimal Treatment Decision for Brain Metastases of Unknown Primary Origin: The Role and Timing of Radiosurgery [PDF]

, 2017
BACKGROUND: Up to 15% of all patients with brain metastases have no clearly detected primary site despite intensive evaluation, and this incidence has decreased with the use of improved imaging technology.
정현호, 박용구, 장원석, 한현진, 장종희   +4 more
core   +1 more source